Abacavir/lamivudine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Abacavir/lamivudine
Combination of
Abacavir Nucleotide analogue reverse transcriptase inhibitor
Lamivudine Nucleotide analogue reverse transcriptase inhibitor
Clinical data
MedlinePlus a696011
Pregnancy cat. C (US)
Legal status POM (UK) -only (US)
Routes Oral
Identifiers
CAS number  YesY
ATC code J05AR02
PubChem CID 5273759
NIAID ChemDB 225604
 YesY (what is this?)  (verify)

Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom.[1] It is a fixed dose combination of lamivudine (3TC, Epivir) and abacavir (ABC, Ziagen).

Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).

It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.

References[edit]